Drug intelligence / Profile preview

Ophtholic Ultra

Development stage
Phase 4
Lead developer
Sentiss Pharmaceuticals
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Ophtholic Ultra is a preservative-free, sterile ophthalmic solution containing a combination of 0.4% sodium hyaluronate and 0.2% tamarind seed polysaccharide. Developed and manufactured by Sentiss, it is designed for the intensive hydration, lubrication, and protection of the ocular surface in patients suffering from dry eye disease (dry eye syndrome) and other ocular surface disorders. Sodium hyaluronate acts as a viscoelastic lubricant that mimics the aqueous layer of the natural tear film, promoting corneal epithelial healing and moisture retention. Tamarind seed polysaccharide is a natural mucoadhesive polymer that mimics ocular mucin, prolonging the residence time of the solution on the ocular surface. Together, these components provide synergistic, long-lasting relief from dryness, irritation, and discomfort, and are utilized post-operatively to prevent and correct ocular surface disturbances following cataract surgery.

Brand names
Ophtholic UltraОфтолик Ультра
Other names
sodium hyaluronate + tamarind seed polysaccharidetamarind seed polysaccharide + sodium hyaluronate

Beyond the preview

Go deeper on Ophtholic Ultra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophtholic Ultra.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call